Optimizing eConsent for Patient Centricity

Over the past few years, the gastroenterology diagnostic market has witnessed an increase in commercial multiplex diagnostic assays for the detection of a large array of enteric pathogens. These multiplex assays differ in many aspects, one important difference being the number of enteric pathogens that the assays detect. Updated IDSA/SHEA guidelines for the management of infectious diarrhea describe a targeted approach, directing proper test utilization for the diagnosis of infectious diarrhea. The guidelines can assist with the development of targeted testing algorithms to diagnose the enteric pathogens most likely causing disease. This patient-centric targeted testing approach can be supported by using the BD MAX ™ system, which uses separate testing panels for the detection of C. difficile, bacterial, parasitic, and viral pathogens.

Intratumor heterogeneity (ITH) is a major underlying cause of therapy resistance and disease recurrence and is a read-out of how a tumor has grown. Current methods to analyze genetic ITH rely on the sequencing of ‘bulk’ or flow-sorted populations, in which the spatial context of tumor subclones is not preserved, and rare subclones may not be detected. These shortfalls can be addressed with BaseScope™ ISH–a unique mutation-specific RNA in situ hybridization assay. The BaseScope assay represents a significant technical advance for in situ mutation detection and provides new insight into the mechanisms of tumor evolution with potential ramifications for selecting patients for treatment. Join us to learn more about this new approach to ITH analysis.

We are entering a new era in which real-world evidence is transforming how drugs are developed, approved, and commercialized. As FDA leads the change with a 3-year strategy—the Framework for FDA’s Real-World Evidence Program—the industry is launched on a shared learning process to understand where and when RWE can support regulatory decision-making. This webcast brings together industry experts in research and pharma to explore how forward-thinking pharmaceutical organizations are adopting new approaches for the use of RWE in drug development and approval.

Low frequency Raman spectroscopy has been used to study various polymorphs and can be applied to the design of crystallization control strategy. Extending the low frequency spectral region to include the fingerprint region provides access to collective vibrations of molecules in the amorphous and crystalline states and yields valuable insight when differentiation of various forms is quintessential.